switching between glp-1 agonists ada receptor in the treatment of type 2 diabetes – state-of-the-art Mechanisms of action of GLP-1

Adjustment Phase After the initial phase, the dose is usually increased to 5 mg once a week for 4 weeks, followed by a second increase to 7.5 mg once a week

The convergence of nitric oxide modulation, actin dynamics, and oxidative stress management supports investigation into layered signaling systems involved in cellular and tissue responses

Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration

These pharmacokinetic data allow a once-weekly subcutaneous injection regimen

Subsequent experiments were designed to examine the effects of intracerebroventricular (i.c.v.) injections of thymulin on cerebral inflammation induced by i.c.v